Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of protein vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of such a vaccine platform. The structured and standardized assessment provided by the template would also help contribute to improved public acceptance and communication of licensed protein vaccines.
All Keywords
【저자키워드】 COVID-19, Vaccine, Safety, peptide, Protein, recombinant, Brighton Collaboration, CEPI, Benefit-risk, Template,
【저자키워드】 COVID-19, Vaccine, Safety, peptide, Protein, recombinant, Brighton Collaboration, CEPI, Benefit-risk, Template,